Therefore, we performed a Cox regression analysis to screen mRBPs that are potentially associated with immune evasion in patients who participated in the IMvigor210 cohort study,[12] which investigated the efficacy of anti‐PD‐L1 antibody in patients with advanced BLCA. This evidence concerns the gene CD274 and bladder transitional cell carcinoma.